GSK is gearing up for the launch of Arexvy, its respiratory syncytial virus (RSV) vaccine for older people, and is counting on efficacy data to persuade US payers of its value in ongoing contract negotiations.
Arexvy is the UK-headquartered company’s most important launch for many years, as it hopes the vaccine can generate around $3bn...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

